dasotraline dasotraline dasotraline (inn; former developmental code name sep-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (sndri) that was under development by sunovion for the treatment of attention-deficit hyperactivity disorder (adhd) and binge eating disorder (bed). structurally, dasotraline is a stereoisomer of desmethylsertraline (dms), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (ssri) antidepressant sertraline (zoloft). dasotralineidentifiers iupac name (1r,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine cas number675126-05-3 ypubchem cid9947999chemspider8123611 nunii4d28ey0l5tkeggd10700 ychemblchembl3301595comptox dashboard (epa)dtxsid20217855 chemical and physical dataformulac16h15cl2nmolar mass292.20 g·mol−13d model (jsmol)interactive image smiles c1c(c2=cc=cc=c21c3=cc(=c(c=c3)cl)cl)n inchi inchi=1s/c16h15cl2n/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16h,6,8,19h2/t11-,16+/m0/s1key:srpxsiljhwnfmk-meduhntesa-n ny (what is this?) (verify) adverse effects in phase i clinical trials for adhd, test subjects reported the following side effects: loss of appetite dehydration dry mouth nausea insomnia anxiety panic attacks headaches history in 2017, the u.s. food and drug administration accepted sunovion's new drug application (nda) for review for the treatment of adhd; however, the nda was ultimately rejected citing the need for additional studies to determine efficacy and tolerability. in july 2019, sunovion’s nda for the treatment of bed was accepted with an expected action date of may 2020. in may 2020, sunovion halted its drug development program for dasotraline, withdrawing both ndas for adhd and bed.